Breast cancer is the most common secondary malignancy among women treated for childhood cancer. This review highlights interacting etiologies contributing to development of secondary breast cancer to complement guidelines for surveillance and survivorship care and make recommendations for clinical practice. Treatment exposures determine Children's Oncology Group breast cancer surveillance guidelines; those treated with cumulative doses ≥20 Gy chest irradiation should undergo annual magnetic resonance imaging and mammography after age 25 years or 8 years after exposure, whichever comes last. Recent investigations suggest that those treated with cumulative doses ≥10 Gy in fields affecting breast tissue, specifically whole lung, should be counseled for similar surveillance. Childhood sarcoma and leukemia survivors treated with anthracyclines and/or alkylating agents without radiation have increased risk for breast cancer and may require enhanced surveillance. Multigene testing and/or genomic evaluation for predisposition among certain childhood cancer subtypes may prove to be beneficial in identifying those at greatest risk. Pediatric oncology nurses who incorporate this information into survivorship care planning discussions/documents and clinical research endeavors may help reduce breast cancer-related morbidity/mortality for this at-risk population.
Breast cancer is the most common secondary malignancy among young women who are childhood cancer survivors (Armstrong et al., 2011; Dorffel, Riepenhausen, Luders, Bramswig, & Schellong, 2015; Friedman et al., 2010; Lee et al., 2016; Reulen et al., 2011; Schaapveld et al., 2015; Turcotte et al., 2015; Turcotte et al., 2017; Wong et al., 2016) . The purpose of this review is to further explore the evidence and extend current understanding for the incidence and risk factors for breast cancer among a diverse and aging population of childhood, adolescent, and young adult female cancer survivors in order to make clinical practice recommendations. The identification of risk indicators could substantially modify outcomes by informing surveillance decisions and preventive interventions that may grant at-risk children additional years of healthy adult life. First, this analysis will summarize observational studies published prior to 2010 on which current Children's Oncology Group (COG) highrisk guidelines are based (COG, 2013) . Second, recent data will be reviewed regarding breast cancer risk in women after treatment for a childhood cancer. Treatment exposures to be evaluated include any dose or field of radiation therapy and/or chemotherapy and associated risk modifiers. Third, pediatric oncology practitioners' clinical practice recommendations for ongoing follow-up surveillance and survivorship care will be discussed in light of current understandings regarding risk of developing secondary breast cancer.
Background
Mortality from secondary malignancies in female childhood cancer survivors has declined (Armstrong et al., 2016) . Nevertheless, new cancers are among the most psychologically traumatic of late effects and even when not fatal, can have lifelong impact on quality of life (Ness et al., 2017) . Secondary breast cancer affects 5% of childhood cancer survivors after 30 years since their primary diagnosis, with a standardized incidence ratio (SIR) of 9.8 in comparison with the general population (Friedman et al., 2010) . Observational studies evaluating therapeutic chest radiation among female childhood cancer survivors, and its correlation to development of secondary breast cancer, provide well-documented examples of this late effect of treatment. The majority of data were from women cohorts of Hodgkin lymphoma survivors treated with full-mantle field radiation with doses 40 to 44 Gy (Bhatia et al., 1996; Bhatia et al., 2003; Constine et al., 2008; De Bruin et al., 2009; Guibout et al., 2005; Hancock, Tucker, & Hoppe, 1993; Inskip et al., 2009; Kenney et al., 2004; Ng, Bernardo, & Weller, 2002; Travis et al., 2003; Wolden, Lamborn, Cleary, Tate, & Donaldson, 1998) .
Among the seminal sources for understanding secondary breast cancer among childhood cancer survivors is the Childhood Cancer Survivor Study (CCSS) . Initiated in 1994, this ongoing multi-institution initiative has established a large and well characterized cohort of 5-year survivors of childhood and adolescent cancer, treated between 1970 and 1986, and more recently expanded for those treated until 1999 ). In women with secondary breast cancer in the CCSS, the odds ratio for breast cancer increased linearly after chest radiation with an estimated relative risk of 6.4 for a dose of 20 Gy and reaching over 11-fold for local breast doses of 40 Gy relative to no radiation (Inskip et al., 2009) .
Mammography and magnetic resonance imaging (MRI) can detect breast cancer in childhood cancer survivors treated with chest radiation (Freitas et al., 2013; Ng et al., 2013) . The 2 screening modalities complement each other in detection of early stage disease in women who were treated with chest radiation for childhood-onset Hodgkin lymphoma (Horst et al., 2016; Ng et al., 2013; Tieu et al., 2014) . Early diagnosis of secondary breast cancer is especially important for survivors of Hodgkin lymphoma as 5-year breast cancer survival in these patients is strongly associated with stage at diagnosis (Henderson, Amsterdam, et al., 2010) . Treatment options are limited in these women because of prior therapeutic exposures to anthracyclines and chest radiation. With appropriate and timely surveillance, secondary breast cancer can be addressed and managed earlier and likely reduce the morbidity and mortality associated with its treatment (Elkin et al., 2011; Hodgson, Cotton, Crystal, & Nathan, 2016) .
Current Practice Guidelines
Standardized risk-exposure schema screening guidelines offered by pediatric oncology surveillance guideline groups such as the COG and the International LateEffects of Childhood Cancer Guidelines Harmonization Group (Harmonization Group), recommend that beginning at puberty, women and girls treated with chest irradiation for a childhood cancer in doses ≥10 Gy, perform monthly self-exam and undergo an annual clinical breast exam; the clinical breast exam should be biannual after the age of 25 years (COG, 2013; Mulder et al., 2013) . With the expectation of reducing the risk of breast cancer−related morbidity and mortality, these groups strongly recommend that women and girls treated with chest irradiation for childhood cancer in doses ≥20 Gy are at high risk and should additionally be screened with annual mammogram and MRI at 8 years posttreatment or at the age of 25 years, whichever occurs last (COG, 2013; Mulder et al., 2013) . The current COG and Harmonization Group standardized guidelines and exposure-risk recommendations are driven by expert consensus and, for the most part, are based on evidence from observational cohort studies from literature published prior to 2010 (COG, 2013; Landier et al., 2004; Mulder et al., 2013) .
Although the Harmonization Group guidelines concur with the exposure-risk schema screening measures currently suggested by COG, they additionally underscore that there is no clear cutoff for a safe chest radiation dose (Mulder et al., 2013) . Therefore, clinical judgment and other relevant risk factors (patient preference, breast density, age, family history) are to be taken into practitioners' consideration regarding promotion for dual imaging surveillance measures for those women who were treated with chest radiation doses <20 Gy. Exposure-risk recommendations for hematopoietic stem cell transplant (HSCT) are guided by pre-HSCT therapy as well as transplant conditioning therapy such as total body irradiation (TBI; COG, 2013; Majhail et al., 2012) . No breast-specific COG guidelines or exposure-risk recommendations exist however, for females exposed to radiation treatments within radiation fields not directly overlying or adjacent to breast tissue with possible scatter exposure, or treatments that include chemotherapy without radiation.
Clinical Practice Decisions
Pediatric oncology practitioner decision making pertaining to appropriate breast surveillance recommendations and preventive strategies for cancer survivors with varied treatment exposures can be limited by the lack of accurate prediction models to guide them. In more contemporary therapy, children and adolescents are treated with lower doses of radiation and reduced volume of exposed tissue, yet breast cancer risk still remains substantial across the decades (Ness et al., 2017; Turcotte et al., 2017; Zhou et al., 2016) . Algorithm-driven survivorship care-planning based strictly on the numerical radiation exposure values offered by the existing guidelines, may be underestimating risk. Survivors may not be counseled for screening if they do not precisely meet the currently defined criteria for high risk, but may be counseled based on more recent data. Thus, regularly revisiting and critical evaluation of recent literature is important for pediatric oncology practitioners.
Literature Review

Methods
A 2-step review of the literature was performed. First, the references listed in the COG (2013) guidelines served as the evidence for benchmarking the review and were all published before 2010.
Second, a literature review was performed to identify literature since 2010, which was guided by the following question. What therapeutic exposures or treatment effect modifiers among females diagnosed with childhood cancer at <21 years of age affect the risk for secondary breast cancer as compared with women in the general population or compared with childhood cancer survivors with different treatment exposures, effect modifiers, or cancer subtype? Clinical or pathologic characteristics of breast cancer as identified in these studies were also of interest.
Inclusion criteria for the updated review included retrospective cohort, population, and case control studies in which SIR, relative risk, absolute excess risk, and cumulative incidences of breast cancer are delineated for female childhood cancer survivors treated for a childhood cancer at <21 years of age. Other inclusion criteria were that they were published in the English language between January 2010 and March 2017.
Electronic databases PubMed, Scopus, and CINAHL were searched between December 2016 and March 2017. PubMed was searched using MeSH terms: Neoplasms (with subheading drug therapy or radiotherapy, or hematopoietic stem cell transplant) and (infant or child or adolescent or young adult) and survivors (used as MeSH term and keyword) and Breast Neoplasms-limited by English, last 7 years, and excluded case reports, letters, reviews and editorials. Scopus was searched using keywords: breast and (cancer or neoplasm* or carcinoma* or lymphoma*) and (risk or incidence) and survivor* and (child* or pediatr* or paediatr* or young)-limited by English and 2010-2017 publication years. CINAHL was searched using exact subject heading Neoplasms (with subheading drug therapy or radiotherapy or hematopoietic stem cell transplant) and Cancer Survivors and Breast Neoplasms (with subheading epidemiology or risk factors)-limited by excluding MEDLINE records.
Results
Key findings for the literature reviews are described in each section, beginning with the evidence base for COG guidelines, and followed by findings from the updated review of literature. The 16 publications included in our updated review are summarized by treatment exposure category (Table 1 , columns A and B). These updates include 8 retrospective cohort studies (Danner-Koptik et al., 2013; Henderson et al., 2016; Lange et al., 2014; Moskowitz et al., 2014; Moskowitz et al., 2015; O'Brien, Donaldson, Balise, Whittmore, & Link, 2010; Schaapveld et al., 2015; Schellong et al., 2014) , 3 retrospective population-based studies (Dores, Anderson, Beane Freeman, Fraumeni, & Curtis, 2010; Swerdlow et al., 2012; VeitRubin et al., 2012) , and 5 retrospective case control studies (Best et al., 2011; Cooke et al., 2013; Horst et al., 2014; Little et al., 2014; Ma et al., 2012) .
Chest Irradiation Exposures
Fields, Doses, Volumes, and Latency. Henderson, Amsterdam, et al.'s (2010) systematic review of the incidence of secondary breast cancer among women treated before the age of 30 years with chest radiation for pediatric or young adult cancer directly informed the current COG recommendations. The SIRs for secondary breast cancer varied between 13.3 and 55.5 and cumulative incidences varied between 12% and 26% at 25 to 30 years follow-up (Bhatia et al., 2003; Constine et al., 2008; Kenney et al., 2004) . Importantly, risk increased as early as 8 years following chest radiation without plateau over an increasing length of follow-up. The median time between the radiation and diagnosis of secondary breast cancer was 15 to 20 years after the radiation. The risk of bilateral involvement was increased with chest radiation; 3 studies evaluating Hodgkin lymphoma survivors treated with chest radiation showed that 12.8% had bilateral disease, with 5.5% synchronous and 7.3% metachronous occurrences (Henderson, Amsterdam, et al., 2010) . This is in contrast to studies of breast cancer in the general population where 3% to 5% of cases show bilateral disease, about half of which are synchronous and half metachronous (Henderson, Amsterdam, et al., 2010) . Cancers were more frequently found in the upper/outer quadrant and within or at the margin of the radiation field (Henderson, Amsterdam, et al., 2010) . With this review (Henderson, Amsterdam, et al., 2010) as a benchmark, recent cohort studies expanded the evaluation of secondary breast cancer risk after treatment to those with various doses, fields, and treatment volumes of chest radiation and to survivors with other various cancer subtypes who had received chest radiation (Lange et al., 2014; O'Brien et al., 2010; Moskowitz et al., 2014; Schaapveld et al., 2015; Schellong et al., 2014; Swerdlow et al., 2012) . Recent studies confirm the high risk of secondary breast cancer among young women Hodgkin lymphoma survivors treated at younger than 21 years with various fields and doses of radiation (Moskowitz et al., 2014; O'Brien et al., 2010; Schaapveld et al., 2015; Schellong et al., 2014; Swerdlow et al., 2012) . For women younger than 20 years who received >40 Gy mantle radiation without alkylating chemotherapy or pelvic radiotherapy, the cumulative risk for secondary breast cancer at 10, 20, 30, and 40 years after treatment was 0.4, 7.6, 28.3, and 47.9%, respectively, with the majority of risk occurring in the latter years . A cohort of female childhood-onset Hodgkin survivors demonstrated a similar latency period after treatment to onset of breast cancer with chemotherapy and low-dose chest radiation of 15 to 25.5 Gy involved field (O'Brien et al., 2010) . Schellong et al. (2014) evaluated data collected from women who were treated in 5 consecutive pediatric Hodgkin lymphoma treatment studies with radiation dose to the supradiaphragmatic fields ranging from 20 to 45 Gy. Women in this series had a frequency of breast cancer that was 24 times as high as in the corresponding general population (Schellong et al., 2014) . Schaapveld et al. (2015) observed that between 1965 and 2000 an increased use of less extensive supradiaphragmatic radiation fields was used to treat Hodgkin lymphoma and the risk for breast cancer decreased by 65% compared with those who were exposed to a mantle field. The overall elevated incidence of radiation-induced breast cancer, however, did not decrease during those decades. Moskowitz et al. (2014) evaluated female participants from the CCSS with Hodgkin lymphoma as well as multiple cancer subtypes, for the purpose of determining the risk of secondary breast cancer associated with various chest radiation doses and fields. The investigators (Moskowitz et al., 2014) observed that childhood cancer survivors treated with lower delivered doses of radiation (median 14 Gy; range 2-20 Gy) to a larger volume of breast tissue (whole lung field) had a high risk of breast cancer compared with the general population (SIR = 43.7), as did survivors treated with high doses of radiation (median 40 Gy; range 5-54 Gy) to the mantle field (SIR = 24.2). That is, the cumulative incidences of breast cancer were similar among women who received whole lung or mantle radiation and were elevated as compared with those who received mediastinal radiation. The magnitude of breast cancer risk by age 50 years for this cohort of women treated for Hodgkin lymphoma and for women who received whole lung radiation for other cancers were comparable with the cumulative risk of breast cancer among BRCA 1 carriers, which was 31% (confidence interval [CI] = 15-48) and higher than for BRCA 2 carriers (Moskowitz et al., 2014 cancer-specific mortality at 5 and 10 years after diagnosis was 12% and 19%, respectively, with no difference in survival by dose of chest radiation, and substantially elevated over expected age and year standardized to the US population (Moskowitz et al., 2014) . A trend also existed for an elevated breast cancer risk in women treated with TBI and abdominal field irradiation, although these results should be interpreted cautiously because of small numbers. Lange et al. (2014) assessed female participants in a cohort of nephroblastoma survivors from the National Wilm's Tumor Studies 1 to 4 for incident breast cancer. Standard treatment of pulmonary metastasis in patients with Wilm's tumor includes 12 to 15 Gy radiation therapies to the entire chest (whole lung). The cumulative rate of invasive breast cancer at age 40 years for women who received chest radiation therapy for metastatic Wilm's tumor was 14.8% (CI = 8.7-24.5). The SIRs relative to the US population for this group was 27.6 (CI = 16.1-44.2; Lange et al., 2014) . Latency ranged from 7.9 to 35.7 years with a median of 27.1 years.
Age at Time of Chest Irradiation Treatment.
Among more recent international case control, treatment cohort and population studies, the risk of secondary breast cancer is particularly elevated for women treated for Hodgkin lymphoma with chest radiation around puberty at 10 to 16 years of age (Cooke et al., 2013; Schellong et al., 2014; Swerdlow et al., 2012) .
Premature Ovarian Insufficiency Induced by Ovarian Irradiation and/or Alkylating Agents in Those Treated With Chest
Irradiation. Moskovitz et al. (2014) and Swerdlow et al. (2012) corroborate older cohort studies (Constine et al., 2008; Inskip et al., 2009; Kenney et al., 2004; Travis et al., 2003; van Leeuwen et al., 2003) in finding that pelvic radiation ≥5 Gy has a protective effect on radiation-induced breast cancer. Such patients still experience excess breast cancer risk, but the excess is less than it would have been without ovarian irradiation (Inskip et al., 2016) .
A protective effect of alkylating agent chemotherapy on radiation-induced breast cancer has been observed in combined cohorts of childhood and adult-onset Hodgkin lymphoma survivors in both pre-2010 and newer studies (DeBruin et al., 2009; Schappveld et al., 2015; Swerdlow et al., 2012; Travis et al., 2003; van Leeuwen et al., 2003) . Nevertheless, alkylating agents were not found to be protective in cohorts of childhood-onset cancers alone (Kenney et al., 2004; Moskowitz et al., 2014) . These findings suggest that the effect of chemotherapy-induced premature menopause may be influenced by age at exposure and that the protective effect might not become evident until this cohort ages.
Genomics as an Effect Modifier to Chest Irradiation. Two variants at chromosome 6q21 associated with breast cancer in
Hodgkin lymphoma survivors treated with chest radiation therapy as children, but not as adults, were recently described by Best et al. (2011) . The variants comprise a risk locus associated with decreased basal PRDM1 expression (a radiation-responsive tumor suppressor also known as BLIMP1), and impaired induction of PRDM1 by radiation exposure. Similarly, Ma et al. (2012) identified the FGFR2 genetic variation as influencing radiation-induced breast cancer among Hodgkin lymphoma survivors especially those treated at young ages (<20 years) and those not treated with ovarian-toxic agents-the groups with the greatest treatment-related risks. These observations (Best et al., 2011; Ma et al., 2012) suggest that a gene-exposure interaction may be implicated in the etiology of radiation-induced breast cancer in childhood-onset Hodgkin lymphoma survivors as well as in other childhood cancer subtypes treated with chest radiation therapy.
Pathologic Correlations to Breast Cancer After Chest Irradiation.
The pathologic features of secondary breast cancer resulting from chest radiation among childhood cancer survivors were observed by Henderson, Amsterdam, et al. (2010) . Histology and hormone receptor status of breast tumors and human epidermal growth factor receptor 2 (HER2) statuses appeared similar to that of women in the general population. There was a prevalence of invasive ductal histology and estrogen and progesterone hormone receptor positivity. These findings were corroborated by Elkin et al. (2011) in a case control study of childhood and adult-onset Hodgkin lymphoma survivors. Horst et al. (2014) more recently demonstrated different observations. Among patients with invasive breast cancer, breast cancers after Hodgkin lymphoma were almost 3 times more likely to be triple negative (estrogen receptor [ER]-negative, progesterone receptor [PR]-negative, HER2-negative) compared with age-matched controls (39% vs 14%). Similar histologic distribution was observed for those younger and older than 30 years at the time of radiation treatment (Horst et al., 2014) . These newer data (Horst et al., 2014) , along with other recent population studies of combined childhood-and adultonset Hodgkin lymphoma (Dores et al., 2010; Veit-Rubin et al., 2012) suggest that chest radiation therapy in Hodgkin lymphoma-associated breast cancer may be more aggressive compared with sporadic cases.
Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
Female cancer survivors who underwent allogeneic HSCT between 1969 and 2000 for a childhood or adult cancer were found to be at increased risk for secondary breast cancer (SIR = 2.2 [CI = 1.7-2.9]) as determined by a multi-institutional cohort study of 3337 women (Friedman et al., 2008) . In multivariate analysis, increased risk was associated with use of TBI (HR = 4.0), and younger age at transplantation (HR = 9.5 for HSCT < 18 years; Friedman et al., 2008) . A paucity of more recent data exists regarding the risk of breast cancer and HSCT in childhood cancer survivors. Danner-Koptik et al. (2013) assembled a cohort of pediatric autologous HSCT recipients from a multi-institutional bone marrow transplant registry and observed an SIR = 93 (CI = 11-336) for secondary breast cancer following autologous HSCT. They could not demonstrate an association between secondary breast cancer risk and age, cancer subtype, or use of TBI or etoposide as part of pretreatment conditioning regimen due to a small number of cases, which limits the clinical usefulness of the data for exposure-risk screening recommendations (Danner-Koptik et al., 2013) .
Radiotherapy to the Orbit for Retinoblastoma
Hereditary retinoblastoma associated with the germline RB1 has been linked to second cancer development, including breast cancer (Marees et al., 2008) . Recently, the relationship of breast cancer risk to radiation (primarily scatter radiation from primary treatment to the orbit) and genetic susceptibility of retinoblastoma survivors was analyzed by performing case control studies of breast cancer in heritable and nonheritable retinoblastoma survivors from the United States and United Kingdom (Little et al., 2014) . The analyses demonstrated that among nonheritable retinoblastoma cases, a high and statistically significant radiogenic risk of breast cancer exists in contrast to the lack of evidence for radiogenic risk among heritable retinoblastoma cases. The analyses also found an elevated risk of breast cancer in heritable retinoblastoma patients who were not treated with radiation (SIR = 8.72). These observations suggest that there may be an additional genetic factor apart from RB1 raising risk in the radiation exposed nonheritable retinoblastoma and possibly for the nonexposed heritable retinoblastoma subtypes (Little et al., 2014) .
Craniospinal Irradiation for Leukemia and Central Nervous System Tumors
Exposure to craniospinal irradiation is not delineated in the current COG surveillance guidelines. A study from the CCSS among survivors of leukemia and central nervous system (CNS) tumors observed an SIR = 2.4 (CI = 0.8-7.5) in all women treated with spinal irradiation, and 3.8 (CI = 1.2-11.7) in leukemia survivors (Moskowitz et al., 2015) . Though leukemia survivors had lower delivered doses of spinal irradiation than the CNS tumor survivors, their estimated doses to the breast were similar, an average of 1.1 Gy compared with 1.5 Gy for leukemia and CNS tumor survivors, respectively (Moskowitz et al., 2015) . The investigators suggest that the increased risk observed in leukemia survivors may be attributable to other risk factors such as genetic factors and highlight the known association of leukemia and breast cancer in a TP53 mutation in Li-Fraumeni Syndrome (Moskowitz et al., 2015) . The study was limited by a small sample size and the cohort's young age at the time of assessment; thus, there was insufficient data to report on breast cancer risk after the age of 40 (Moskowitz et al., 2015) . The investigators found little evidence to support a recommendation for early breast cancer screening targeting women exposed to spinal irradiation for a childhood cancer. Henderson et al. (2016) recently investigated breast cancer risk among childhood cancer survivors in the CCSS without a history of chest radiotherapy; risks were especially increased after treatment for sarcoma and leukemia. The cumulative incidence of breast cancer by the age of 45 years was 4.5% overall (CI = 3.2%-6.2%), and 5.8% and 6.3% in survivors of sarcoma and leukemia, respectively; this corresponded to a 4-to 5-fold increased risk compared with the general population. Alkylating agents and anthracyline containing chemotherapy were associated with increased breast cancer risk in a dosedependent manner; nevertheless, the agent-specific contributions or their interaction could not be assessed. In sarcoma and leukemia survivors exposed to anthracycline and alkylator chemotherapy, risk was increased almost 10-fold as compared with the general population. Breast cancer presented in women as young as 22 years with a median age at breast cancer diagnosis of 38 years. Latency ranged from 10 to 34 years with a median of 24 years. Fifteen percent of women presented with bilateral disease ; this estimate is comparable to that observed in previous reports of breast cancer survivors exposed to chest radiotherapy and higher than the incidence of bilateral disease observed in the general population (Henderson, Amsterdam, et al., 2010) .
Chemotherapy Without Chest Irradiation
In a commentary on the results of the study by Henderson et al. (2016) , van Leeuwen and Ronckers (2016) pointed out to practitioners that both sarcoma and breast cancers are known to be associated with Li-Fraumeni syndromes with inherited or de novo mutations in the tumor suppressor gene TP53. They go on to say that acute leukemia was originally also described as 1 of the 6 defining malignancies, although much less common in Li-Fraumeni syndrome families compared with sarcoma. The commentators raise the question as to whether increased risk of breast cancer in the Henderson et al. (2016) report is solely due to chemotherapy exposures or to genetic predisposition in combination with chemotherapy (van Leeuwen & Ronckers, 2016) .
Discussion
Research has further clarified, identified, confirmed, and/ or suggested the treatment exposures, effect modifiers, and the interplay of genomics and genetics that increase secondary breast cancer risk among female childhood cancer survivors and complement current guidelines for surveillance and survivorship care. Pediatric oncology practitioners should translate this added evidence into clinical practice and research considerations for riskstratified anticipatory guidance (Table 1) .
Implications for Evidence-Based Practice
Clinical and Image-Based Survivorship Screening Recommendations. Integrating the evidence from recent publications into the clinical decision-making process, helps refine a practitioner's anticipatory guidance to focus on the total levels of therapeutic radiation exposure to areas overlying or near breast tissue that should prompt recommendations for dual image screening. Primarily, it confirms the observed risks of the currently identified high-risk population (ie, ≥20 Gy of chest radiation) as highlighted in the guidelines of the COG (2013), and fortifies the recommended breast cancer surveillance parameters for this population irrespective of cancer subtype (Moskowitz et al., 2014; O'Brien et al., 2010; Schellong et al., 2014; Swerdlow et al., 2012) . Additionally, updated publications add substantial evidence to clarify interpretation of COG recommendations. They offer compelling justification for identical surveillance with dual annual MRI and mammography beginning 8 years after treatment, for those treated with lower doses of chest radiation (10-19 Gy), to a greater volume of tissue, such as whole lung radiation (Lange et al., 2014; Moskowitz et al., 2014) . Recent observations of estrogen and progesterone receptor negativity and aggressive pathology among secondary breast cancer after Hodgkin lymphoma (Dores et al., 2010; Horst et al., 2014; Veit-Rubin et al., 2012) further imply a need for timely screening in this population and also challenge the notion that these women should be candidates for chemoprevention with selective estrogen receptor modulators or aromatase inhibitors which are only thought to be effective in prevention of estrogen receptor positive tumors (Fisher et al., 1998) .
Premature ovarian insufficiency may attenuate radiation-induced breast cancer (Cooke et al., 2013) . Although a protective effect of pelvic irradiation ≥5 Gy (Moskowitz et al., 2014; Swerdlow et al., 2012) and alkylating agent chemotherapy (Schaapveld et al., 2015; Swerdlow et al., 2012) exists among those treated with chest radiation, excess risk among these women was still observed (Inskip et al., 2016) , though less so without these exposures, and thus should not alter anticipatory guidance.
Clinical Implications for Genomics and Genetic Screening Recommendations. In the current COG (2013) guidelines, a family history for breast cancer is to be taken into consideration for anticipatory surveillance guidance based on data from Kenney et al. (2004) suggesting that family history of breast cancer increases risk of secondary breast cancer in childhood cancer survivors who undergo chest radiation. This recommendation is supported because women treated for childhood-onset Hodgkin lymphoma with a first-degree relative with breast cancer have an increased risk of secondary breast cancer when compared with Hodgkin survivors without such family history (Sud, Thomsen, Sundquist, Houlston, & Hemminki, 2017) . Recent studies are pointing to the impact of genomic and genetic evaluations in childhood cancer survivors in those without a family history of breast cancer.
Secondary breast cancer researchers have recently noted a similarity in the extent of increased risk for breast cancer in BRCA 1 and BRCA 2 gene mutation carriers and the increased risk for secondary breast cancer in childhood-onset cancer treated with chest radiation (Henderson, Amsterdam, et al., 2010; Moskowitz et al., 2014) . A genomic-exposure interaction has been implicated in chest radiation-induced breast cancer among childhood-onset Hodgkin survivors and may underpin breast cancer risk (Best et al., 2011; Ma et al., 2012) . In the future, molecular tools such as gene-expressing polymorphism assays may allow for further defining the determinants of chest radiation-induced toxicity and offer a more targeted approach toward treatment decisions, surveillance parameters, and anticipatory survivorship education.
When Henderson et al. (2016) evaluated sarcoma and leukemia survivors without radiation therapy, they observed an enhanced incidence of secondary breast cancer. Commentators, however, suggested that genetic predisposition may be at play and may guide surveillance parameters in the near future (van Leeuwen & Ronckers, 2016) . Likewise, Moskowitz et al. (2015) postulated that genetic factors may attribute to findings of a modestly increased risk of secondary breast cancer among leukemia survivors who received spinal irradiation. Clinical utility for genetic testing for childhood cancer patients and survivors with sarcoma and/or leukemia on chemotherapy alone and/or who have received spinal irradiation with or without a family history of breast cancer remains a fundamental issue to address; surveillance not otherwise considered may be indicated, and/or preventive strategies or treatments may be available.
Researchers conducted a large-scale genomic study of children diagnosed with cancer before the age of 20 years to consider the utility of broad genetic testing among this population (Zhang et al., 2015) . Unexpected germline mutations associated with breast cancer predisposition syndromes were found in patients with Ewing's sarcoma, neuroblastoma, osteosarcoma, or leukemia. Among the most common identified were TP53 and BRCA2. The majority (60%) of children with a hereditary cancer predisposition mutation in the study by Zhang et al. (2015) did not have a family history of cancer. These results suggest that pathogenic mutations in TP53 and BRCA 2 are more common in pediatric cancer than previously recognized and may potentially underpin secondary breast cancer among these survivors.
The recent findings from Zhang et al. (2015) , combined with the reports from Henderson et al. (2016) and Moskowitz et al. (2015) , provocatively suggest that considering multigene test screening for breast cancer predisposition syndromes such as TP53 and BRCA 1 and BRCA 2 be routinely incorporated into clinical care of children with sarcoma and leukemia, even in the absence of a family history of breast cancer. This consideration may also apply to children with both heritable and noninheritable forms of retinoblastoma with and without radiation treatment exposure, based on the findings of Little et al. (2014) . For the patient, identification of hereditary mutations may influence recommendations for late effect screening measures and guide family planning. For the patient's relatives, having this information can prompt them to request their own genetic testing and/or consider cancer prevention measures. Pediatric oncology practitioners in the treatment setting have the responsibility to be informed about the genetics and genomics of second cancer predisposition and should anticipate providing patients and families with information about potential benefits and challenges as the science develops.
Implications for Nurse Practitioner-Led New Models of Survivorship Education.
Barriers to compliance with breast cancer surveillance can be addressed and mitigated by nurse practitioner-led education of survivors and their parents as pediatric oncology survivors emerge from the pediatric treatment environment and beyond. A lack of information/education and anticipatory risk-based guidance regarding secondary breast cancer curtails survivors' ability to prepare, understand, reframe, and accept their current and future surveillance parameters (Bober, Park, Schmookler, Nancarrow, & Diller, 2007; Crom, Hinds, Gattuso, Tyc, & Hudson, 2005; Smith et al., 2010) . Because of the complex and comprehensive nature of survivorship education, combined with possible neurocognitive late-effects, multiple educational approaches over time may be necessary to be effective. Models of nurse practitioner-led adolescent and young adult survivorship care are emerging in academic, community, and research settings which reinforce and promote appropriate surveillance strategies (Carlson, Hobbie, Brogna, & Ginsberg, 2008; Corcoran, Dunne, & McCabe, 2015; Kinahan et al., 2015) . Several targeted sessions of nurse practitioner-led risk-based education in a long-term follow-up clinic of adolescent and young adult survivors have been effective in raising a survivor's awareness for these healthy-survivorship practices (Landier et al., 2015) . Pediatric oncology practitioners should assist cancer survivors adapt to the medical and psychological implications of secondary breast cancer. It is essential to teach breast self-exam, encourage survivors to take an active role in managing their future health, and promote partnerships with associates of engagement, such as parents, for adult-oriented follow-up care (Szalda et al., 2017) .
Implications for Survivorship Care Plan Documents. Survivors and their parents should not be the sole repository of surveillance and risk-based care parameters. Guidelines are only helpful if health care providers as well as the patients are aware of them and have an understanding for their unfolding nuances. One study demonstrated that among women aged 25 to 39 years who were treated with chest radiation for a childhood-onset cancer, only 37% of these high-risk survivors reported receiving a mammogram within the past 2 years and 47% had never had a mammogram (Oeffinger et al., 2009) . The most important predictor of having had a mammogram was the recommendation of a physician. Yet both oncology and nononcology providers have endorsed a need for guidance because of their lack of familiarity with the unique health risks associated with treatment exposures for childhood cancer survivors (Henderson, Hlubocky, Wroblewski, Diller, & Daugherty, 2010; Nathan et al., 2013; Suh et al., 2014) .
Survivorship care plans are recommended for all cancer survivors and now mandated for adult cancer survivors (Commission on Cancer, 2012; Hewitt, Greenfield, & Stovall, 2005; Hewitt & Simone, 2003) . They pose one important solution to surveillance screening and appropriate risk-based care. Serving as a roadmap for posttreatment care, the plans are created by an oncology provider and are understandable for both patients and other health care providers (Commission on Cancer, 2012; Hewitt, Greenfield, & Stovall, 2005; Hewitt & Simone, 2003) . Nurse practitioner-led education of pediatric oncology patients and their families with dedicated survivorship care planning discussions supplemented by a survivorship care plan document, which can be shared with health care providers throughout a survivor's life, can serve as key systemic facilitators to childhood cancer survivors' appropriate and timely risk-based health care.
Implications for Research.
Nurse practitioner-facilitated research by the CCSS is in progress and is impacting the trajectory of surveillance for women at high risk for secondary breast cancer by empowering them with various educational interventions . A randomized intervention trial among high-risk women aged 25 to 39 years, which includes a tailored intervention (mailed information about surveillance recommendations, followed up with a telephone-delivered reinforcement and motivational interview by a nurse practitioner), increased mammography surveillance rates among those survivors as compared with those who were mailed general information only . On the basis of consistently identified secondary breast cancer risk among childhood-onset Hodgkin lymphoma survivors, nurse practitioner-led high-risk breast research clinics are providing opportunities for aftercare surveillance and data accrual for design of future treatment regimens, preventive measures, and surveillance strategies (Dorfell, Riepenhausen, Luders, & Bramswig, 2016) . As academic medical centers with research programs are addressing these surveillance issues for childhood cancer survivors who are transitioning to adult care, it is imperative to spread the standard of care to centers where these survivors are treated in the community. To that end, pediatric oncology research efforts will need to continue focusing on transitional strategies that measure and promote survivor-management readiness among the survivors themselves, their parents, and their primary care providers (Schwartz et al., 2013) .
Conclusion
Pediatric oncology nurses have the privileged presence of watching their patients emerge from the treatment setting. Delineating and teaching the nuances of preventive strategies and screening recommendations to both patients and their health care providers begin with pediatric oncology practitioners. It is their responsibility to maintain continued awareness and understanding for the interplay of risk factors, effect modifiers, family history, genomics, and genetics that influence the development of breast cancer among childhood cancer survivors, in an effort to provide appropriate anticipatory guidance to pediatric oncology patients as they look forward to a healthier adult future.
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